Pfizer Inc. (NYSE:PFE) Given Average Recommendation of "Moderate Buy" by Brokerages

Pfizer Inc. (NYSE:PFE - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seventeen analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $31.07.

A number of research analysts have recently issued reports on PFE shares. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group decreased their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th.

Pfizer Price Performance

NYSE:PFE traded up $0.19 during trading hours on Friday, reaching $22.10. The company had a trading volume of 61,888,490 shares, compared to its average volume of 40,318,735. The firm has a market capitalization of $125.34 billion, a PE ratio of 15.67, a PEG ratio of 0.64 and a beta of 0.67. The stock has a 50-day moving average of $25.25 and a two-hundred day moving average of $26.38. Pfizer has a one year low of $20.92 and a one year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the company posted $0.10 EPS. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. Analysts forecast that Pfizer will post 2.95 earnings per share for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company's stock.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Pfizer by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after purchasing an additional 2,923,537 shares during the last quarter. Norges Bank bought a new stake in shares of Pfizer in the fourth quarter valued at about $2,328,986,000. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.